The US Food and Drug Administration (FDA) has approved the first generic version of the estradiol and levonorgestrel transdermal system (Climara Pro), expanding treatment options for women with an intact uterus who require hormone therapy for moderate to severe menopausal vasomotor symptoms or prevention of postmenopausal osteoporosis, according to an agency press release.
The once-weekly patch is manufactured by Zydus Pharmaceuticals and contains estradiol and levonorgestrel, delivering 0.045 mg and 0.015 mg per day, respectively. The FDA determined that the generic is therapeutically equivalent to the branded product.
The patch combines an estrogen and a progestogen in a single transdermal system. Unlike estrogen-only formulations, the combination is intended for women with an intact uterus, with levonorgestrel included to reduce the risk of endometrial hyperplasia associated with unopposed estrogen exposure.
The approval does not introduce a new active ingredient, indication, or route of administration. Rather, it provides a generic alternative to an existing branded treatment with the same approved uses.
Generic drug approval relies on demonstrating pharmaceutical equivalence and bioequivalence to the reference product, rather than repeating the full clinical efficacy program conducted for the original medicine. New comparative efficacy trial results were not reported in the agency announcement.
The estradiol and levonorgestrel patch is contraindicated in patients with undiagnosed abnormal genital bleeding, breast cancer or a history of breast cancer, estrogen-dependent neoplasia, active or previous deep vein thrombosis or pulmonary embolism, and active or previous arterial thromboembolic disease. Additional contraindications include hepatic impairment or disease, hypersensitivity to either component, and certain thrombophilic disorders.
The FDA identified application-site reactions, vaginal bleeding, breast pain, upper respiratory tract infections, back pain, depression, pain, headache, and flu syndrome among adverse reactions occurring in at least 5% of patients.
The therapy carries the established risks associated with systemic estrogen-progestogen treatment, including cardiovascular and thromboembolic events and certain malignancies. Treatment decisions should account for individual risk factors, particularly when hormone therapy is considered solely for osteoporosis prevention.
The FDA has not announced the generic patch's commercial availability or pricing, but has noted to contact Zydus Pharmaceuticals for availability information.
Source: FDA
